CORRECTIONS

Author Corrections

The September 10, 2009, *Diagnosis in Oncology* article by Davids et al, entitled “Response to a Novel Multitargeted Tyrosine Kinase Inhibitor Pazopanib in Metastatic Merkel Cell Carcinoma” (*J Clin Oncol* 27:e97-e100, 2009), contained an error in the spelling of the first author’s name. It was origi-

nally given as Matthew Davids and should have been Matthew S. Davids. The authors apologize to the readers for the mistake.

DOI: 10.1200/JCO.2010.30.5680

The February 1, 2010, article by Shen et al, entitled “DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes” (*J Clin Oncol* 28:605-613, 2010), contained an error.

In Figure 3, some of the data depicted in the bar graph were incorrect for decitabine (DAC), complete remission and partial remission (CR/PR), hematologic improvement (HI), stable disease (SD), and progressive disease (PD). The corrected figure is reprinted below in its entirety.

The online version has been corrected in departure from the print. The authors apologize to the readers for the mistake.

DOI: 10.1200/JCO.2010.30.5698

Journal Correction

The May 1, 2010, article by Sekeres et al, entitled “Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes” (*J Clin Oncol* 28:2253-2258, 2010), contained an error in the spelling of the fifth author’s name. It was originally given as Rebecca Ganetsky

and should have been Rebecca Ganetzky. *Journal of Clinical Oncology* apologizes to the authors and readers for the mistake.

DOI: 10.1200/JCO.2010.30.5706